Birchview Capital, LP Castle Biosciences Inc Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Birchview Capital, LP holds 110,600 shares of CSTL stock, worth $2.51 Million. This represents 2.38% of its overall portfolio holdings.
Number of Shares
110,600
Previous 88,404
25.11%
Holding current value
$2.51 Million
Previous $1.77 Million
27.64%
% of portfolio
2.38%
Previous 1.59%
Shares
11 transactions
Others Institutions Holding CSTL
# of Institutions
165Shares Held
27.2MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.04MShares$69.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$49.3 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.8MShares$40.9 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.49MShares$33.8 Million2.2% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$31.3 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $597M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...